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SUMMARY Narrow-band UVB has been reported to be efficacious 
in patients with vitiligo. The epidermis of patients with vitiligo 
showed reduction in the levels of catalase, in association with high 
levels of hydrogen peroxidase (H2O2) that is toxic for melanocytes. 
Based on these findings, we studied the efficacy and safety of a 
topical gel containing catalase and superoxide dismutase (Vitix®) 
in combination with narrow-band UVB. The study included 22 
patients of which 19 completed the 6-month study period. Patients 
applied the gel containing catalase and superoxide dismutase 
twice a day and received narrow-band UVB 3 times per week. Two 
different dermatologists evaluated the grade of repigmentation by 
photograph comparison. At the end of therapy, more than 50% of 
overall repigmentation was noticed in 11 of 19 (57.9%) patients. 
More than 75% repigmentation was recorded in three (15.79%), 
26%-50% repigmentation in six (31.58%) patients and 1%-25% 
repigmentation in one (5.26%) patient, whereas one (5.26%) of 19 
patients showed no repigmentation at all. The best response was 
achieved on the face and neck, with more than 50% repigmentation 
observed in 11 of 14 (78.6%) patients. Development of new lesions 
was not observed. Adverse events were mild and transient. The 
study showed that the combination therapy of narrow-band UVB 
and gel containing catalase and dismutase is a therapeutic option 
that could be considered in the management of vitiligo. Further 
evaluation of this combination in multicenter, double-blind, placebo-
controlled studies should be undertaken.
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INTRODUCTION
 Vitiligo is an acquired idiopathic hypomelanot-
ic disorder characterized by sharply demarcated 
depigmented macules of variable size and shape 
(1). The incidence is 1%-2% without sexual pre-
dilection (2,3). Functional melanocytes disappear 
from the lesional area of the epidermis although 
some authors have shown that melanocytes are 
still present even in the long-standing disease (4). 
The exact pathogenesis of vitiligo remains un-
known. Several hypotheses on the pathogenesis 
exist, e.g., autoimmune, neural, self-destruction 
and biochemical, however, none is fully explana-
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tory (3,5). The biochemical hypothesis on the 
melanocyte destruction in vitiligo in part refers to 
excessive production of oxidation products such 
as hydrogen peroxidase (H2O2) and low catalase 
activity in keratinocytes of the involved and unin-
volved epidermis (3,6-8), which was demonstrat-
ed in vivo and in vitro (6,7). The overproduction 
of H2O2 is the result of high levels of monoamine 
oxidase A and of a defective recycling of tetrahy-
drobiopterin, which is an essential cofactor for the 
hydroxylation of phenylalanine to tyrosine via phe-
nylalanine hydroxylase (9). The H2O2 overproduc-
tion could also account for the low catalase activity 
in keratinocytes (9).
 According to this hypothesis, we conducted a 
study to investigate the efficacy and safety of a 
topical formulation containing catalase and super-
oxide dismutase (Vitix®) in combination with nar-
row-band UVB phototherapy in 22 patients.
PATIENTS AND METHODS
 Study design
 The study was open and uncontrolled. Patients 
were screened at a preliminary visit. Reviews were 
made monthly at each visit. The duration of the 
study was 6 months.
 Patients
 Nineteen patients with vitiligo (6 males and 13 
females) from the outpatient clinic of the Univer-
sity Department of Dermatology and Venereology, 
Zagreb University Hospital Center, were included 
in the study. Three patients dropped out because 
of their non-compliance and not because of ad-
verse effects. The mean age of study patients was 
29.28, range 15-71 years.  The clinical vulgaris 
subtype was present in 14, acrofacial type in 3 pa-
tients, and segmental and focal type in one patient 
each. 
 According to Fitzpatrick classification, nine pa-
tients had skin type IV, seven had skin type II and 
three had skin type III. The mean duration of the 
disease was 6.23 years, ranging from 3 months to 
21 years. Family history was positive in three (15.7 
%) cases. Twelve patients were previously treat-
ed: eight with topical corticosteroids, and four with 
PUVA therapy. Seven patients did not receive any 
therapy. Patients using medical treatment for viti-
ligo at the time of the study, patients with a history 
of skin cancer, dysplastic nevi, photosensitivity or 
using photosensitizing medicines, with psychiatric 
or epileptic disorders, renal failure, known sub-
stance allergies, and pregnant and breast-feeding 
patients were not included in the study. All patients 
were healthy and used no additional treatment.
 Treatment protocol
 Patients were assessed and instructed to ap-
ply the skincare gel product containing catalase 
and superoxide dismutase from the plant Cu-
cumis melo (Vitix®, Life Science Inv. Ltd.) to the 
affected skin twice a day for the study period of 
six months. During the treatment period, patients 
were also exposed to the narrow-band UVB three 
times per week. The UVB source was a Wald-
mann-UV7001K. The first dose was 0.25 mJ/cm2. 
Doses were gradually increased depending on the 
patient’s response to the previous exposure. Dur-
ing the treatment, the eyes were protected by UV-
blocking goggles. All patients kept their underwear 
on in order to shield the genitals from the narrow-
band UVB exposure. Patients applied Vitix® gel 
much before taking phototherapy.
 Evaluation of the treatment
 Patients were seen monthly for clinical follow 
up, close-up photo-documentation and reassess-
ment. Therapeutic response was expressed as 0% 
(no repigmentation), 1%-25% (poor), 26%-50% 
(moderate), 51%-75% (good) and 76%-100% 
(excellent) repigmentation. The repigmentation 
grade was estimated by two different dermatolo-
gists who compared the photographs.
 The total number of treatments, cumulative 
narrow-band UVB dose, and adverse effects were 
recorded.
RESULTS
 The χ2-test and Mann-Whitney test were used 
on statistical evaluation. The level of significance 
was set at p<0.05. Twenty-two eligible patients 
were enrolled in the study. Three patients dropped 
out because of their non-compliance and not be-
cause of adverse effects, and 19 patients were 
evaluated for therapeutic efficacy. The mean num-
ber of narrow-band UVB exposures was 68.89 
(range 63-74). The mean total UVB dose per pa-
tient was 41.67 J/cm2 (range 30.10-67.65 J/cm2). 
The first repigmentation occurred between the 6th 
and 26th exposure (mean 12.6 exposure).  
 At the end of the 6-month therapy, more than 
50% of overall repigmentation was noticed in 11 
of 19 (57.9%) patients. Of these, three (15.79%) 
patients showed more than 75% (excellent) re-
pigmentation, six of 19 (31.58%) patients showed 
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26%-50% (moderate) repigmentation, one (5.26%) 
patient showed 1%-25% (poor) repigmentation, 
and one (5.26%) patient showed no repigmenta-
tion at all.     
 Certain anatomic sites responded better than 
the others. The best response was achieved in 
the lesions located on the face and neck, followed 
by proximal extremities and trunk. Lesions on the 
hands and feet were most refractory to treatment. 
More than 50% repigmentation on the face and 
neck was recorded in 11 of 14 (78.6%) patients. Of 
these, five (35.7%) patients showed excellent re-
pigmentation (Fig. 1). More than 50% repigmenta-
tion on proximal extremities and trunk was record-
ed in nine of 17 (52.9%) patients. Of these, five 
(29.4%) patients showed excellent repigmentation. 
More than 50% repigmentation on the hands and 
feet was observed in five of 13 (38.5%) patients. 
Excellent repigmentation on the hands and feet 
was seen in two (15.4%) patients (Fig. 2).  
 There was no significant correlation between 
the disease duration and repigmentation grade 
(p=0.311), type of the skin and repigmentation 
grade (p=0.223), and previous therapy and repig-
mentation (p=0.477). 
 The development of new lesions was not re-
corded in our patients. Laboratory evaluation of 
serum and urine was unremarkable.  
Thirteen of 19 (68.4%) patients reported mild ery-
thema on depigmented areas, one (5.26%) patient 
reported mild erythema with stinging and itching at 
the site of Vitix® gel application, and five patients 
were free from side effects.
DISCUSSION
 Although vitiligo is asymptomatic and does not 
affect mortality and physical morbidity, depigmen-
tation on visible areas leads to severe cosmetic 
disfigurement and may cause considerable psy-
Figure 1.
A) Vitiligo on the face of an 18-year-old female 
patient
Figure 2.
A) Vitiligo on the dorsum of the hands of a 30-
year-old female patient
Figure 1.
B) Almost complete repigmentation after 6-month 
therapy
Figure 2.
B)  Excellent repigmentation after 6-month therapy
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chological distress. Patients with vitiligo have nu-
merous treatment options available, but not all pa-
tients respond to the current treatment methods. 
Even among patients who respond to the treat-
ment, there is a high potential for relapse. 
 Phototherapeutic options (narrow-band UVB 
and PUVA) are relatively efficacious in the treat-
ment of generalized vitiligo. They are generally 
limited by the requirement of long-term treatment 
on a twice or three times a week basis for 12 
months or even longer. Narrow-band UVB (311 
nm) is considered as the first-choice therapy for 
adults and children with generalized vitiligo (5,10). 
Narrow-band UVB is equally or more efficacious 
than PUVA (11,12). Various studies report more 
than 75% repigmentation in 12.5%-75% of pa-
tients after one year of UVB narrow-band treat-
ment (13-18).
 The advantages of narrow-band UVB over oral 
PUVA therapy include the following: shorter treat-
ment time; no systemic effects since oral drugs 
are not required; less burning incidents; less con-
trast formation between depigmented and normal 
pigmented skin: no need of post-treatment eye 
photoprotection; and allowed use in children and 
pregnant and lactating women (5,19). The mecha-
nism of action of narrow-band UVB phototherapy 
in vitiligo is not completely understood. It induces 
local immunosuppression, stimulates the produc-
tion of melanocyte-stimulating hormone, and in-
creases melanocyte proliferation and melanogen-
esis (20).
 Nowadays, there is accumulating evidence 
that the increased oxidative stress exists in the 
entire epidermis of these patients. Oxidation prod-
ucts such as hydrogen peroxide (H2O2) are toxic 
for melanocytes (7). The involved and uninvolved 
epidermis of patients with vitiligo showed a consis-
tent reduction in the levels of catalase, a scaven-
ger for highly reactive substances, in association 
with high levels of H2O2 (8). Based on these ob-
servations, a low-molecular weight complex called 
pseudocatalase has been synthesized. It has 
been hypothesized that epidermal H2O2 can be re-
moved with topical application of a narrow-band 
UVB-activated pseudocatalase cream and such 
a combination has been tried in the treatment of 
vitiligo. In an uncontrolled study, 33 patients with 
vitiligo were treated with a twice-a-day application 
of pseudocatalase, calcium and narrow-band UVB 
twice a week. Complete repigmentation on the 
face and dorsum of the hands appeared in 90% 
of treated patients over a mean of 15 months (9). 
In another open, uncontrolled study, topical pseu-
docatalase in combination with narrow-band UVB 
showed no clear evidence of efficacy and there 
was even a slight tendency to worsening of the pa-
tients’ vitiligo. The treatment period was 6 months 
(21). Thus, the use of pseudocatalase in the treat-
ment of vitiligo remains a controversial issue. 
 In our study, at the end of 6-month therapy, 11 
(57.9%) patients achieved more than 50% repig-
mentation. Only two (10.52%) patients showed 
poor or no repigmentation at all. The face and 
neck showed the best repigmentation response 
(78.6% of patients had more than 50% repigmen-
tation). Lesions on the hands and feet were most 
refractory to treatment, yet our patients showed 
better results in these areas (38.5% of patients 
achieved 50% repigmentation) than patients in 
other studies where narrow-band UVB therapy 
was used (12,13,16,17). The duration of our study 
was not sufficient to achieve complete therapeutic 
response and this is probably the reason why only 
three (15.79%) patients achieved more than 75% 
overall repigmentation. For example, in the study 
by Westerhof et al., only 8% of patients showed 
more than 75% repigmentation of the lesional skin 
at 3 months (18). However, at 12 months of treat-
ment, 63% of patients showed more than 75% re-
pigmentation on the lesional skin. 
 There is no consensus whether better re-
sponse to the narrow-band UVB treatment cor-
relates with a shorter duration of the disease or 
darker skin type. We found no correlation between 
the rate of response and disease duration or skin 
type.  
 In our study, no progression of the disease 
was observed during the treatment period. Vitix® 
gel was well tolerated and only one patient report-
ed mild erythema with stinging and itching at the 
application site. 
 The manufacturer claims that this formulation, 
containing two free radical scavengers (catalase 
and superoxide dismutase) is an effective catalyst 
for the removal of H2O2 from the skin. However, 
another report indicates that Vitix® does not have 
a capacity to reduce H2O2 (22). Although our study 
was open and uncontrolled, most of the repigmen-
tation observed could probably be attributed to the 
narrow-band UVB therapy, however, an additional 
effect of Vitix® gel is quite possible. 
 In conclusion, the present study showed that 
the combination therapy with narrow-band UVB 
and topical catalase and dismutase of a natural 
origin (Vitix®) is a therapeutic option that could be 
considered in the management of vitiligo. Further 
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evaluation of this combination in multicenter, dou-
ble-blind, placebo-controlled studies should be 
undertaken. 
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